Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30

$1.66−0.03 (-1.78%)

Close on Nov 12, 2026Market cap $590.23MP/E –Yield –

Evotec statistics

74 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Dec 31, 2025
Share price as of: –

Valuation ratiosIndustry

Market Cap: €529.16M; €783.71M
Enterprise Value: €192.14M; €551.25M
PS Ratio: 0.67; 7.00
PB Ratio: 0.65; 0.65
P/TBV Ratio: 1.04; 1.33

Enterprise valuationIndustry

EV / Sales: 0.24; 4.00
EV / EBITDA: 4.44; 6.50

Share statisticsIndustry

Shares Outstanding: 178M; 100M
Shares Change (YoY): 0.16%; 5.61%
Float: 147M; 79M
Shares Held by Insiders: 17.1%; 9.05%
Shares Held by Institutions: 1.82%; 20.8%

Short sellingIndustry

Short Interest: 63,321; –
Short Interest Change: -17.2%; -2.55%
Days to Cover: 1.00; 3.54

Stock price statisticsIndustry

Price Change (1 Week): -6.48%; 3.30%
Price Change (1 Month): 16.5%; 4.20%
Price Change (3 Months): -15.3%; -15.8%
Price Change (6 Months): -39.0%; -17.6%
Price Change (YTD): -46.1%; -12.8%
Price Change (1 Year): -44.1%; -19.5%
Price Change (3 Years): -82.3%; -3.74%
Price Change (5 Years): -93.0%; -54.2%
Price Change (10 Years): -40.0%; -41.5%
Average Volume (10 Days): 81,417; –
Average Volume (20 Days): 77,951; –
Average Volume (90 Days): 99,231; –
Relative Volume: 0.48; 0.96
Relative Strength Index (14): 53.9; 51.0
Volatility (1 Year): 56.5%; 65.1%
Beta (5 Years): 1.25; 0.87

MarginsIndustry

Gross Margin: 14.5%; 42.5%
Operating Margin: -7.13%; -33.2%
Pretax Margin: -11.0%; -36.6%
EBITDA Margin: 5.49%; -28.6%
FCF Margin: -10.4%; -24.4%

Returns on capitalIndustry

Return on Invested Capital (ROIC): -7.72%; 6.28%
Return on Capital Employed (ROCE): -4.18%; -23.8%

Financial positionIndustry

Current Ratio: 2.07; 3.49
Quick Ratio: 1.51; 1.51
Debt / Equity: 0.10; –
Debt / EBITDA: 1.88; –
Net Debt / EBITDA: -7.79; –

GrowthIndustry

Revenue Growth (YoY): -1.08%; -1.08%
Revenue Growth (3Y CAGR): 1.61%; 1.61%
Revenue Growth (5Y CAGR): 9.49%; 14.0%

EfficiencyIndustry

Asset Turnover: 0.43; 0.31
Inventory Turnover: 22.31; 1.36
Revenue Per Employee: €173.16K; €855.98K
Employee Count: 4,553; 304
WACC: 10.4%; 9.33%

Income statement (TTM)Industry

Revenue: €788.37M; €465.66M
Gross Profit: €114.22M; €1.08B
Operating Income: -€56.22M; -€54.01M
Pretax Income: -€86.77M; -€47.40M
EBITDA: €43.26M; -€42.85M
EPS (Diluted): -0.58 EUR; -0.55 EUR

Balance sheetIndustry

Cash & Short-Term Investments: €418.52M; €199.29M
Total Debt: €81.50M; €184.06M
Net Cash (Debt): €337.02M; €111.50M
Net Cash Per Share: 1.90 EUR; 1.53 EUR
Equity (Book Value): €813.70M; €472.30M
Book Value Per Share: 4.58 EUR; 6.00 EUR
Tangible Book Value: €509.77M; €50.66M
Working Capital: €394.87M; €119.55M

Cash flow (TTM)Industry

Operating Cash Flow: -€9.18M; -€42.16M
Capital Expenditures: -€72.54M; -€2.34M
Free Cash Flow: -€81.72M; -€52.90M
FCF Per Share: -0.46 EUR; -0.48 EUR

Dividends and yieldsIndustry

FCF Yield: -15.4%; -13.2%
Buyback Yield: 0.29%; -11.1%
Shareholder Yield: 0.29%; -11.1%

Taxes and interestIndustry

Income Tax: €16.75M; €80.00K

Scores and fair valueIndustry

Altman Z-Score: 0.35; 1.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	EVO	S&P 500	Difference	EVO per year	S&P 500 per year
1 month	+21.2%	-2.7%	+23.9 pts
3 months	-24.2%	-1.7%	−22.5 pts
Year to date	-46.1%	+11.9%	−58.0 pts
1 year	-47.1%	+12.0%	−59.1 pts
3 years	-82.2%	+78.2%	−160.4 pts	-43.8%	+21.2%
5 years	-93.0%	+73.2%	−166.2 pts	-41.2%	+11.6%
10 years	-40.0%	+309.6%	−349.7 pts	-5.0%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M EVO shares were sold short on Oct 30, 2026, down 17.2% from the previous report. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 51.6% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	63,321	-17.2%	69,432	1.0
Oct 15, 2026	76,498	+246.7%	131,778	1.0
Sep 30, 2026	22,066	-78.5%	241,452	1.0
Sep 15, 2026	102,492	+12.1%	60,373	1.7
Aug 31, 2026	91,437	+80.2%	36,520	2.5
Aug 14, 2026	50,740	+6.5%	85,727	1.0
Jul 31, 2026	47,630	+68.6%	48,877	1.0
Jul 15, 2026	28,249	-46.7%	65,895	1.0
Jun 30, 2026	53,014	-18.4%	37,318	1.4
Jun 15, 2026	64,975	-13.4%	30,470	2.1
May 29, 2026	75,029	+13.0%	30,727	2.4
May 15, 2026	66,393	-22.9%	68,739	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Evotec's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Oct 20, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Compare: EVO vs PTGX · EVO vs HCM · EVO vs RARE · EVO vs AAPG · EVO vs TLX

Revenue growth-1.1% · median 15.8%

Operating margin-7.1% · median -64.0%

Company	Revenue	Growth
EVO	€788.37M	-1.1%
RARE	$730.00M	+15.8%
PTGX	$551.69M	+163.7%
HCM	$204.89M	-4.3%
AAPG	–	–
TLX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 4,553
Auditor: BDO AG Wirtschaftsprufungsgesellschaft
SEC CIK: 1412558

Advertisement
300 × 250

See a number that looks wrong?